Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review

Area of Science:

• Biomaterials Science
• Tissue Engineering
• Regenerative Medicine

Background:

• Vascularization is a key limitation in tissue engineering, hindering the size and complexity of engineered tissues.
• Restoring blood flow is crucial for ischemic tissue repair, but no FDA-approved pro-angiogenic treatments are currently available.
• Existing pre-clinical pro-angiogenic approaches face challenges, including the lack of effective delivery systems.

Purpose of the Study:

• To review pro-angiogenic peptides and their potential in tissue engineering.
• To discuss biomaterial delivery systems suitable for peptide therapeutics.
• To emphasize the importance of controlled release systems for improving peptide pharmacokinetics.

Main Methods:

• Literature review of pro-angiogenic peptides and biomaterial delivery systems.
• Analysis of advantages of peptide-based therapeutics over protein-based treatments.
• Focus on depot-based delivery systems for controlled peptide release.

Main Results:

• Pro-angiogenic peptides offer advantages in synthesis and stability compared to proteins.
• Current biomaterial development for drug delivery predominantly focuses on proteins, not peptides.
• Peptides, like proteins, exhibit poor in vivo pharmacokinetics, necessitating controlled release strategies.

Conclusions:

• Development of effective biomaterial delivery systems is critical for advancing pro-angiogenic peptide therapeutics.
• Depot-based systems show promise for overcoming pharmacokinetic limitations of peptides in tissue engineering.
• Further research into peptide-specific delivery systems can enhance vascularization and tissue regeneration.